Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Immunological adjuvants promote activated T cell survival via induction of Bcl-3.

Mitchell TC, Hildeman D, Kedl RM, Teague TK, Schaefer BC, White J, Zhu Y, Kappler J, Marrack P.

Nat Immunol. 2001 May;2(5):397-402.

PMID:
11323692
2.

Stronger correlation of bcl-3 than bcl-2, bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival.

Mitchell TC, Teague TK, Hildeman DA, Bender J, Rees WA, Kedl RM, Swanson B, Kappler JW, Marrack P.

Ann N Y Acad Sci. 2002 Dec;975:114-31.

PMID:
12538159
3.
4.

Bystander virus infection prolongs activated T cell survival.

Mitchell T, Kappler J, Marrack P.

J Immunol. 1999 Apr 15;162(8):4527-35.

5.

A short domain within Bcl-3 is responsible for its lymphocyte survival activity.

Mitchell TC, Thompson BS, Trent JO, Casella CR.

Ann N Y Acad Sci. 2002 Dec;975:132-47.

PMID:
12538160
7.
8.

Enhanced basal AP-1 activity and de-regulation of numerous genes in T cells transgenic for a dominant interfering mutant of FADD/MORT1.

Chaneva S, Schneider G, Siegmund D, Wajant H, Mages J, Häcker G.

Eur J Immunol. 2004 Nov;34(11):3006-15.

10.

A1 is a growth-permissive antiapoptotic factor mediating postactivation survival in T cells.

Gonzalez J, Orlofsky A, Prystowsky MB.

Blood. 2003 Apr 1;101(7):2679-85.

11.

IL-12-programmed long-term CD8+ T cell responses require STAT4.

Li Q, Eppolito C, Odunsi K, Shrikant PA.

J Immunol. 2006 Dec 1;177(11):7618-25.

12.

Transgenic Bcl-3 slows T cell proliferation.

Bassetti MF, White J, Kappler JW, Marrack P.

Int Immunol. 2009 Apr;21(4):339-48. doi: 10.1093/intimm/dxp002.

13.

4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.

Kroon HM, Li Q, Teitz-Tennenbaum S, Whitfield JR, Noone AM, Chang AE.

J Immunother. 2007 May-Jun;30(4):406-16.

PMID:
17457215
14.

Genome-wide analysis of gene expression in T cells to identify targets of the NF-kappa B transcription factor c-Rel.

Bunting K, Rao S, Hardy K, Woltring D, Denyer GS, Wang J, Gerondakis S, Shannon MF.

J Immunol. 2007 Jun 1;178(11):7097-109.

15.

Molecular mechanisms of activated T cell death in vivo.

Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P.

Curr Opin Immunol. 2002 Jun;14(3):354-9. Review.

PMID:
11973134
16.

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH.

J Immunol. 2001 Aug 1;167(3):1313-24.

18.

Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.

Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS.

Blood. 2008 Sep 1;112(5):1759-66. doi: 10.1182/blood-2008-04-151068.

19.

Tid1 is required for T cell transition from double-negative 3 to double-positive stages.

Lo JF, Zhou H, Fearns C, Reisfeld RA, Yang Y, Lee JD.

J Immunol. 2005 May 15;174(10):6105-12.

20.

Influence of mucosal adjuvants on antigen passage and CD4+ T cell activation during the primary response to airborne allergen.

Wikstrom ME, Batanero E, Smith M, Thomas JA, von Garnier C, Holt PG, Stumbles PA.

J Immunol. 2006 Jul 15;177(2):913-24.

Items per page

Supplemental Content

Support Center